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Introduction
Implementation of a quality management system has
become standard practice for industries when their products
or services are associated with significant risks to human
safety. Use of a quality management system contributes to
better products and services. It raises consumers’ trust and
confidence; it is associated with stronger customer loyalty,
more repeat sales, less vulnerability to price pressures and
lower marketing expenditures.1,2 As a consequence, “quality
management” has become an essential component of today’s
management strategies.3-7
Use of quality management systems and accreditation has
been advocated as a putative driver for quality, safety and
reduced costs in healthcare as well. First introduced about
two decades ago in hospital pharmacies and laboratories,8
quality management has altered previously established
mechanisms, induced structural changes and promoted high
quality organizational processes. It has improved structures
of health services’ organizations and altered professionals’
attitudes towards external and internal assessment.9-13
Competent authorities, healthcare payers and hospitals
devote increasing resources to quality management systems
and to accreditation or certification of parts or all of their
activities. Still, evidence of improved patients’ outcome is
scarce.14-17 With increasing financial constraints, questions
about the value of the large sums invested in health service
accreditation arose in recent years.17-20
Hematopoietic stem cell transplantation (HSCT) is an
established treatment for many patients with severe congen-
ital or acquired disorders of the hematopoietic system.
Despite major improvements, it remains associated with sub-
stantial morbidity and mortality.21-24 HSCT requires the coop-
eration of many categories of healthcare professionals.
Hence, it presents a role model to assess the value of a quality
management system which defines infrastructures, equip-
ment, release of products or services, responsibilities, training
of personnel, acceptable criteria for admission and discharge,
and requires implementation of standard operating proce-
dures and continuous improvement strategies as key ele-
ments.3-7
In this context, “JACIE” (www.jacie.org) and its US equiva-
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Competent authorities, healthcare payers and hospitals devote increasing resources to quality management sys-
tems but scientific analyses searching for an impact of these systems on clinical outcome remain scarce. Earlier
data indicated a stepwise improvement in outcome after allogeneic hematopoietic stem cell transplantation with
each phase of the accreditation process for the quality management system “JACIE”. We therefore tested the
hypothesis that working towards and achieving “JACIE” accreditation would accelerate improvement in outcome
over calendar time. Overall mortality of the entire cohort of 107,904 patients who had a transplant (41,623 allo-
geneic, 39%; 66,281 autologous, 61%) between 1999 and 2006 decreased over the 14-year observation period by
a factor of 0.63 per 10 years (hazard ratio: 0.63; 0.58-0.69). Considering “JACIE“-accredited centers as those with
programs having achieved accreditation by November 2012, at the latest, this improvement was significantly
faster in “JACIE”-accredited centers than in non-accredited centers (approximately 5.3% per year for 49,459
patients versus approximately 3.5% per year for 58,445 patients, respectively; hazard ratio: 0.83; 0.71-0.97). As a
result, relapse-free survival (hazard ratio 0.85; 0.75-0.95) and overall survival (hazard ratio 0.86; 0.76-0.98) were
significantly higher at 72 months for those patients transplanted in the 162 “JACIE“-accredited centers. No signif-
icant effects were observed after autologous transplants (hazard ratio 1.06; 0.99-1.13). Hence, working towards
implementation of a quality management system triggers a dynamic process associated with a steeper reduction
in mortality over the years and a significantly improved survival after allogeneic stem cell transplantation. Our data
support the use of a quality management system for complex medical procedures.
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ABSTRACT
lent counterpart “FACT” (www.factwebsite.org) have devel-
oped an evolving set of identical standards (kindly provid-
ed initially by FACT and currently in its fifth version) that
require an ongoing quality management system and apply
to clinical, collection and processing activities. Centers
seeking accreditation are subject to a detailed document
review, on-site inspection and auditing procedure as is
used in any industrial total quality management pro-
gram.25,26 A preliminary analysis, based on a small number
of patients transplanted in an accredited center showed a
significant stepwise reduction of early mortality by each
phase of the accreditation process for patients transplant-
ed in accredited centers.27 We, therefore, tested the
hypothesis that improvement in outcome would begin
long before final “JACIE” accreditation, extend during
post-transplant follow-up and hence lead to a more rapid
reduction of mortality over calendar years. 
Methods 
Study design
This retrospective observational analysis was based on a previ-
ously published cohort of the EBMT database; it begins at
January 1st 1999, 3 years before the first center in Europe was
“JACIE”-accredited and ends at December 31st 2006.27
Accreditation status was defined in two different ways: (i)
depending on the particular phase of the accreditation process at
the moment of the transplant (baseline: center had never applied
for accreditation or 3 years before application; preparatory: the 3-
year period before application; application: from application to
accreditation; accreditation: after accreditation); and (ii) depending
on the accreditation status of the respective transplant center in
November 2012 (“JACIEpos”: 49,459 patients; 162 centers;
“JACIEneg”: 58,445 patients; 423 centers). We postulated that the
organizational and cultural changes associated with the introduc-
tion of a quality management system3,9,14 should already be
detectable during the years 1999 to 2006 in centers that achieved
“JACIE” accreditation at any time thereafter.  All EBMT teams are
required to obtain patients’ consent and to have internal review
board approval for evaluation of their transplant programs and
for data transfer to the EBMT. 
Patients
The cohort included 107,904 patients, 59% males, with a first
allogeneic HSCT (n= 41,623; 39%) or autologous HSCT (n=
66,281; 61%) for an acquired hematologic disease (Table 1). 
There were significant changes in the population of patients from
1999 to 2006 with an increasing proportion of acute leukemia and
a relative decrease in chronic leukemia as the main diagnosis and
a steady increase in EBMT risk score.27-29
Statistical analysis 
The focus of the statistical approach was on the interaction
between “JACIE“ accreditation and calendar time on mortality
reduction with adjustments for the key known risk factors. The
main confounders, cluster or stratification variables were: main
disease, EBMT risk score (score points 0-7: age of patient: <20
years = 0, 20-40 years = 1, > 40 = 2; disease stage: early = 0, inter-
mediate = 1, advanced = 2; time interval from diagnosis to trans-
plant: <1 year = 0, >1 year = 1; allogeneic HSCT only: donor type:
HLA identical sibling = 0; other donor = 1; donor-recipient gender
combination: all other = 0, female donor for male recipient = 127-29),
patient’s age, donor type, conditioning, calendar year, center, cen-
ter size analyzed as successive quartiles, and Gross National
Table 1. Characteristics of 107,904 patients, children and adults, who under-
went an allogeneic (n= 41,623; 39%) or autologous (n= 66,281; 61%) HSCT
between 1999 and 2007 in Europe transplanted in a center accredited by
“JACIE” by November 2012 or not. 
Characteristic                                Accredited      Non-accredited          Total
                                                       N=49,459          N=58,445         N=107,904 
                                                          (46%)                 (54%)               (100%)
Donor type
Autologous                                          27,451 (41%)        38,830 (59%)      66,281 (100%)
Allogeneic                                             22,008 (53%)        19,615 (47%)      41,623 (100%)
Syngeneic/HLA-identical sibling   11,268 (49%)        11,615 (51%)     22,883  (55%)*
Other matched family/unrelated  7,225  (59%)         5,073  (41%)      12,298 (30%)*
Mismatched family/unrelated        3,378 (56%)          2,706 (44%)        6,084 (15%)*
Disease
Acute leukemia                                 14,268 (48%)        15,216 (52%)      29,484 (27%)*
Chronic leukemia                              5,084 (53%)          4,568  (47%)        9,652  (9%)*
Lymphoma                                          15,331 (42%)        21,181 (58%)     36,512  (34%)*
Plasma cell disorders                      11,280 (44%)        14,560 (56%)      25,840 (24%)*
Myeloproliferative neoplasms
/myelodysplastic disorders             2,462 (59%)          1,737 (41%)         4,199 (4%)*
Aplastic anemia/bone marrow
failure syndromes                             1,034 (47%)          1,183 (53%)         2,217 (2%)*
EBMT risk score; allogeneic                                                                                       
0+I                                                        3,322 (46%)          3,895 (54%)        7,217 (17%)*
II+III                                                    9,803  (53%)          8,721 (47%)       18,524 (45%)*
IV+V                                                      7,619 (55%)          6,162 (45%)       13,781 (33%)*
VI+VII                                                   1,264 (60%)            837 (40%)           2,101 (5%)*
EBMT risk score; autologous                                                                                      
0+I                                                        1,313 (33%)          2,576 (67%)         3,889  (6%)*
II+III                                                    15,209 (42%)        21,081 (58%)      36,290 (55%*)
IV+V                                                     10,929 (42%)        15,173 (58%)      26,102 (39%)*
Year of transplant
1999                                                       5,511 (47%)          6,120 (53%)     11,631 (10.8%)*
2000                                                       5,646 (47%)          6,395 (53%)     12,041 (11.2%)*
2001                                                       5,848 (47%)          6,596 (53%)     12,444 (11.5%)*
2002                                                       5,923 (45%)          7,302 (55%)     13,225 (12.3%)*
2003                                                      6,140  (46%)          7,128 (54%)     13,268 (12.3%)*
2004                                                      6,488  (46%)          7,727 (54%)     14,215 (13.2%)*
2005                                                      6,917  (45%)          8,613 (55%)     15,530 (14.4%)*
2006                                                       6,986 (45%)          8,564 (55%)     15,550 (14.4%)*
Center size (over centers: allogeneic)
1st quartile (# of trpl)                         637 (30%)            1,562 (70%)         2,199 (5%)*
2nd quartile (# of trpl)                       2,344 (40%)          3,419 (60%)        5,763 (14%)*
3rd quartile (# of trpl)                       4,276 (41%)          6,040 (59%)       10,316 (25%)*
4th quartile (# of trpl)                      14,751 (63%)         8,594 (37%)       23,345 (56%)*
Center size (over centers: autologous)
1st quartile (# of trpl)                         658 (17%)            3,280 (83%)         3,938 (6%)*
2nd quartile (# of trpl)                       2,682 (26%)          7,323 (74%)       10,005 (15%)*
3rd quartile (# of trpl)                       7,386 (40%)         10,900 (60%)      18,286 (28%)*
4th quartile (# of trpl)                      16,725 (49%)        17,327 (51%)      34,052 (51%)*
GNI/cap (over countries)
1st quartile (# of trpl)                       5,041 (20%)         20,348 (80%)      25,389 (23%)*
2nd quartile (# of trpl)                      12,968 (39%)        20,325 (61%)      33,293 (31%)*
3rd quartile (# of trpl)                      10,891 (48%)        11,812 (52%)      22,703 (21%)*
4th quartile (# of trpl)                      20,559 (77%)         5,960 (23%)       26,519 (25%)*
Age (4 classes)
0 to 20 years                                        5,024 (44%)          6,462 (56%)       11,486 (11%)*
20+ to 40 years                                 11,182 (43%)        14,649 (57%)      25,831 (24%)*
40+ to 60 years                                 23,861 (47%)        26,953 (53%)      50,814 (47%)*
Over 60 years                                      9,392 (47%)         10,381 (53%)      19,773 (18%)*
Conditioning (allogeneic)
Standard                                             13,948 (53%)        12,540 (47%)      26,488 (64%)*
Reduced                                              6,479 (57%)          4,965 (43%)       11,444 (27%)*
Not known in database                    1,581 (43%)          2,110 (57%)         3,691 (9%)*
Conditioning (autologous)                                                                                          
Standard                                             14,803 (47%)        16,399 (53%)      31,202 (47%)*
Reduced                                               164 (35%)             304 (65%)            468 (1%)*
Not known in database                   12,484 (36%)        22,127 (64%)      34,611 (52%)*
Percentages reflect row percentages (*column percentages) (Numbers do not always add up,
due to some missing values); trpl: transplanted.
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Income per capita (GNI/cap) of the center’s country24 (data
obtained from www.worldbank.org).
An extended Cox proportional hazards model was chosen.
Cause-specific hazards were calculated, taking relapse and death
as competing risks. Disease and conditioning were considered as
stratification factors, since survival of patients with different dis-
eases was not proportional (Figure 1) and conditioning was not a
target of the analysis. The effect of accreditation was estimated by
using a different baseline within each stratum and averaged over
the categories. All covariates were truly patient-level covariates,
except for “JACIEpos” accreditation, “GNI/cap” and “center size”
which were shared among all patients transplanted at the same
time and place. This “JACIE” variable as defined above served as a
covariate to predict outcome at the patient level, not at the center
level. 
Endpoints in all analyses were overall survival, relapse-free sur-
vival, relapse incidence and non-relapse mortality.28 The interac-
tion terms tested were “JACIE”*size, “JACIE*calendar year,
“JACIE”*age, and “JACIE*GNI/cap.  For reasons of comparability
we evaluated the same models with and without the remaining
significant interaction terms to get a separate as well as a pooled
(adjusted) “JACIE” effect.
Results
There were differences between the groups. Centers
with “JACIE” accreditation by 2012 were more likely to
have performed a higher total number of transplants, to be
in countries with a higher GNI/cap, to perform more allo-
geneic HSCT, to do so with a higher proportion of alterna-
tive donors, to have more patients with a higher EBMT
risk score, and to have fewer missing values.
Main risk factors and outcome after hematopoietic
stem cell transplantation
The outcome of the 107,904 patients treated between
January 1st 1999 and December 31st 2006 by allogeneic
(n=41,623) or autologous (nN=66,281) HSCT (Table 1) was
influenced by type of transplant, main disease, and EBMT
A. Gratwohl et al.
910 haematologica | 2014; 99(5)
Figure 1. The figure depicts the diversity of the popu-
lation of patients and the heterogeneity in outcome
as illustrated by the Kaplan-Meier estimates of over-
all survival for 107,904 patients who underwent allo-
geneic (n=41,623) or autologous (n=66,281) HSCT in
Europe between 1999 and 2006. (A) Allogeneic HSCT
and (B) autologous HSCT showing overall survival by
main disease category (acute leukemia, blue; chronic
leukemia, orange; lymphoma, red; plasma cell disor-
ders, purple; myelodysplastic disorders/myeloprolif-
erative neoplasms, yellow; and bone marrow failure
syndromes, allogeneic only, pink). No P values are
given. The figure simply illustrates the heterogeneity;
the study was not meant to assess differences
between main disease categories. (C) Allogeneic
HSCT and (D) autologous HSCT showing overall sur-
vival depending on EBMT risk score. Allogeneic HSCT:
score 0+I (n=7,217; blue), score II+III (n=18,524; yel-
low), score IV+V (n=13,781; red), and score VI+VII
(n=2,101; lilac). Autologous HSCT: score 0+I
(n=3,889; blue), score II+III (n=36,290; yellow), and
score IV+V (n=39,883; red). The hazard ratios for
increasing risk with increasing score are depicted in
Table 2. (E) Overall survival (OS) of 15,618 patients
with an allogeneic HSCT in 1999 (4,742 patients; OS
at 3 years 47.3%; blue), in 2002 (5,043 patients; OS
at 3 years 50.5%; green) and in 2005 (5,833
patients; OS at 3 years 53.8%; yellow), illustrating the
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risk score (Figure 1).28 The probability of overall survival at
6 years was 47% for recipients of an allogeneic HSCT (non-
relapse mortality 29%, relapse incidence 30%, relapse-free
survival 40%) and 57% for patients who underwent autol-
ogous HSCT (non-relapse mortality 11%, relapse incidence
49%, relapse-free survival 40%) with wide variations
depending on the main disease (Figure 1A,B).
Data showed a systematic decrease in overall and
relapse-free survival related to a systematic increase in non-
relapse mortality and relapse incidence with increasing
EBMT risk score for both allogeneic (Figure 1C) and autol-
ogous (Figure 1D) HSCT [hazard ratio (HR) 1.21; 1.20 to
“JACIE” accreditation and outcome
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Table 2A. Allogeneic HSCT. Probability of overall survival (OS), relapse-free survival (RFS), relapse incidence (RI), and non-relapse mortality (NRM)
after HSCT depending on “JACIE” accreditation status in November 2012 of the respective transplant team, year of transplant and key pre-trans-
plant risk factors. Numbers represent hazard ratios (HR), adjusted for all other risk factors by stratification (see Methods section for details).
                                                                         OS                                          RFS                                            RI                                           NRM
Accreditation in 2012
No, HSCT in1999                                                         1                                                        1                                                          1                                                         1
Yes, HSCT in1999                                           1.04[0.96-1.12]                              1.09 [1.01-1.17]                                1.09[1.01-1.17]                                             
Yes, HSCT 10 years later                              0.86[0.76-0.98]                              0.85 [0.75-0.95]                                0.82[0.70-0.97]                                             
Effect modification per 10                          0.83 [0.71-0.97]                             0.78 [0.67-0.91]                                0.71 [0.57-0.89]                               0.84 [0.68-1.04]
calendar years
Yes, adjusted overall                                   0.97 [0.91-1.03]@                           0.99 [0.94-1.05]@                              1.02 [0.85-1.09]@                              0.97 [0.88-1.06]
Year of HSCT
Baseline1999                                                               1                                                        1                                                          1                                                         1
Per 10 years;                                                  0.70 [0.62-0.79]                             0.75 [0.66-0.85]                               0.90 [0.76-1-08]                               0.62 [0.53-0.74
non-accredited center
Per 10 years; accredited                              0.58[0.53-0.65]                              0.58 [0.53-0.64]                                0.64 [0.56-0.74]                               0.52 [0.45-0.60]
center
Effect modification by accreditation#      0.83 [0.71-0.97]                             0.78 [0.67-0.91]                                0.71 [0.57-0.89]                               0.84 [0.68-1.04]
calendar years
Per 10 years, adjusted, overall                  0.63 [0.58-0.69]@                           0.65 [0.60-0.71]@                              0.75 [0.66-0.84]@                              0.57 [0.51-0.64]
EBMT risk score
Zero                                                                               1                                                        1                                                          1                                                         1
Per two points                                               1.21 [1.20-1.23]                              1.18 [1.17-1.2]                                 1.17 [1.15-1.20]                               1.20 [1.17-1.22]
Donor type                                                                                                                                                                                                                                                      
HLA-identical sibling/syngeneic                             1                                                        1                                                          1                                                         1
Matched other donor                                   1.15[1.09-1.20]                              1.10 [1.05-1.16]                                0.92 [0.86-0.99]                               1.33 [1.24-1.43]
Mismatched donor                                       1.47 [1.37-1.56]                             1.37 [1.30-1.45]                                 1.07 [1.00-1.14                                1.76 [1.62-1.91]
Center size                                                                                                                                                                                                                                                      
1st quartile                                                                    1                                                        1                                                          1                                                         1
Per quartile increase                                   0.95 [0.92-0.98]                             0.96 [0.94-0.99]                                0.97 [0.93-1.00]                               0.95 [0.91-1.00]
GNI/cap                                                                                                                                                                                                                                                            
1st quartile                                                                    1                                                        1                                                          1                                                         1
Per quartile increase                                   0.92[0.85-0.95]                              0.93 [0.91-0.96]                                0.99 [0.95-1.03]                               0.88 [0.84-0.92]
Table 2B. Autologous HSCT.
                                                                         OS                                          RFS                                            RI                                           NRM
Accreditation in 2012                                                                                                                                                                                                                                    
No                                                                                  1                                                        1                                                          1                                                         1
Yes, adjusted                                                  1.03[1.00-1.06]                               1.01[0.99-1.04]                                 1.03[1.00-1.06]                                0.95[0.99-1.00]
Year of HSCT                                                                                                                                                                                                                                                  
Baseline1999                                                               1                                                        1                                                          1                                                         1
Per 10 years, adjusted                                  0.63[0.59-0.67]                               0.79[0.75-0.83]                                 0.83[0.78-0.88]                                0.64[0.57-0.71]
EBMT risk score                                                                                                                                                                                                                                            
0                                                                                     1                                                        1                                                          1                                                         1
Per two points                                                1.17[1.16-1.19]                               1.14[1.13-1.15]                                 1.10[1.09-1.12]                                1.31[1.28-1.34]
Center size                                                                                                                                                                                                                                                      
1st quartile                                                                    1                                                        1                                                          1                                                         1
Per quartile increase                                   0.95[0.94-0.97]                               0.95[0.94-0.97]                                 0.94[0.93-0.96]                                1.00[0.97-1.03]
GNI/cap                                                                                                                                                                                                                                                            
1st quartile                                                                    1                                                        1                                                          1                                                         1
Per quartile increase                                   1.02[1.01-1.04]                              1.02 [1.01-1.03]                                1.03 [1.02-1.04]                               0.97 [0.94-0.99]
#multiplier of the hazard ratio (interaction term in model) for the difference in speed of improvement between accredited and non-accredited centers; @based on a model ignoring
on purpose the above mentioned interaction terms, using only main effects.
1.23 per two score points for overall survival in allogeneic;
HR 1.17; 1.16 to 1.19 in autologous HSCT)]. Overall sur-
vival after allogeneic HSCT was significantly better for
patients with HLA- identical siblings as donors compared
to those with matched other donors (HR 1.15; 1.09 to 1.20)
or mismatched donors (HR 1.47; 1.37 to 1.56). Outcome
improved significantly over time, with an adjusted HR of
0.63 (0.59 to 0.67) for overall survival expressed as
improvement per 10 calendar years (Figure 1E; Table 2). 
Internal quality control: outcome of patients 
and “JACIE” accreditation phase of the transplant team
at the time of the transplant  
The quality control analysis validated the previous find-
ings for patients with an allogeneic HSCT. Overall and
relapse-free survival improved stepwise from baseline (n =
33,753; HR = 1) over the preparatory period (n = 4,890; HR
0.90; 085 to 0.96) and application period (n = 1,922; HR
0.87; 0.80 to 0.95) to the accreditation period (n = 1,058;
HR 0.87; 0.77 to 0.98) for patients who were in that par-
ticular phase of the accreditation process at the moment of
the transplant. Non-relapse mortality and relapse inci-
dence also decreased as systematically. Clustered survival
analysis applied a robust log rank score test, accounted for
random center effects (likelihood ratio test = 13.09;
P=0.0045) and confirmed the previously reported findings
with an additional 5 more years follow-up information.27
In contrast, effects after autologous HSCT (baseline n=
55,762; preparatory 6,799; application 2,487 and accredita-
tion 1,233 phase) were no longer observed.
Reduction in mortality over time for patients 
transplanted between 1999 and 2006 depending 
on working towards and achieving “JACIEpos” 
accreditation status of the transplant team the latest
by November 2012 
The annual improvement over the 14-year observation
period was significantly faster in accredited centers. The
overall mortality rate was decreasing by a factor of 0.58
per 10 years (i.e. 5.3% per year) in “JACIEpos” centers com-
pared to decreasing by a factor of 0.70 per 10 years (i.e.
3.5% per year) in “JACIEneg” centers. This difference in
speed of improvement was statistically significantly in
favor of the accredited centers as estimated by a multiplier
HR (interaction test) for overall survival (HR 0.83; 0.71 to
0.97), relapse incidence (HR 0.71; 0.57 to 0.89) and relapse-
free survival (HR 0.78; 0.67 to 0.91). 
As a consequence, non-relapse mortality (HR 0.86; 0.73
to 1.03) and relapse incidence (HR 0.82; 0.70 to 0.97) were
lower for the 22,008 patients who underwent allogeneic
HSCT in “JACIEpos” centers, resulting in significantly high-
er adjusted overall survival (HR 0.86; 0.73 to 0.98) and
relapse-free survival (HR 0.85; 0.75 to 0.95) (Table 2A).  A
cohort of patients who received an allogeneic HSCT
between 2004 and 2006 illustrates the impact of accredita-
tion on outcome (Figure 2A). Effects were detected in
patients with a low or intermediate (not high) EBMT risk
score, as illustrated by a subgroup of patients transplanted
in a large center (Figure 2B). 
As in the analysis of “JACIE” effects depending on
A. Gratwohl et al.
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Figure 2. “JACIE” accreditation status of the transplant team by
November 2012 and outcome of patients transplanted between
1999 and 2006. (A) Kaplan-Meier estimates of overall survival of
17,655 patients with an allogeneic HSCT, transplanted in the years
2004-2006 in a center accredited (green line; n=8,983) or not (blue
line; n=8,672) by 2012. The respective hazard ratios are presented
in Table 2A. (B) Overall survival (OS) and non-relapse mortality (NRM)
at 72 months by EBMT risk score for 17,243 patients transplanted
with an allogeneic HSCT in a large center accredited by November
2012 (blue line) or not (red line). (C) Overall survival and non-relapse
mortality at 72 months by EBMT risk score for 28,052 patients trans-
planted with an autologous HSCT in a large center accredited by







































0 12 24 36 48 60 72
0,I II,III IV,V VI,VIII 0,I II,III IV,V
accreditation status at the time of transplantation, the data
failed to show a significant effect of “JACIE” accreditation
by 2012 on either reduction of mortality over time or on
any of the four outcomes after autologous transplantation
(n= 66,281; HR 1.03; 1.00 to 1.06; overall survival) (Figure
2C; Table 2B). 
Center size and outcome
Center size (as calculated per calendar year of transplant
and adjusted for type of conditioning) was significantly
associated with all outcomes. Patients who underwent
allogeneic HSCT in large centers had a lower non-relapse
mortality (HR 0.95; 0.91 to 1.00) and relapse-free survival
(HR 0.97; 0.93 to 1.0) resulting in a significantly better
overall survival (HR 0.95; 0.92 to 0.98; per quartile) com-
pared to patients transplanted in a smaller center, and
adjusted for the accreditation effect and all other risk fac-
tors. Patients who underwent autologous HSCT showed
analogous effects except for those on non-relapse mortali-
ty (HR 1; 0.97-1.03): per quartile increase in center size,
the overall survival increased by a HR of 0.95 (0.94-0.97),
the relapse-free survival by 0.95 (0.94-0.97) and the relapse
incidence 0.94 (0.93-0.96).
Of note, the median follow-up of survivors was signifi-
cantly longer among accredited centers (72 versus 61
months) and significantly longer for patients who had allo-
geneic HSCT compared to those who had an autologous
HSCT. This difference may both denote the association
between accreditation and improved follow-up, and lead
to an underestimation of benefits associated with accredi-
tation.
Discussion
These data provide a clear view of the potential impact
of accreditation in medical practice in general and specif-
ically in HSCT. Results became better in all centers over
calendar time but they improved significantly faster and
were more pronounced for patients transplanted in the
context of accredited programs. As a consequence, non-
relapse mortality and relapse incidence were lower, and
relapse-free survival and overall survival were significant-
ly better for patients having received their allogeneic
HSCT in centers accredited for the quality management
system “JACIE” by the year 2012. This difference in out-
come was observed as early as at day 100 and continued
up to 72 months after HSCT. The effects were substan-
tial, systematic and clinically relevant with an overall
improvement of 10-15%. The data suggest that accredita-
tion as an indicator for quality driven work was the single
most important contributing factor to the substantial
improvement over time. More importantly, introduction
of a quality management system can induce visible
changes in a medical team, long before final accreditation.
This fits with observations of quality management sys-
tem work in industrial production.3-7 However, no such
effects could be demonstrated for patients who under-
went autologous HSCT.
The analysis revealed other new findings. Outcome
was significantly and systematically influenced by center
size, GNI/cap and calendar year, in addition to the known
risk factors such as EBMT risk score, age and donor type.
The improvement occurred stepwise, independently of
the accreditation over calendar years. Outcome was bet-
ter, the larger the centers, and the richer their respective
country. The populations of patients changed over time
and differed between centers with accredited and non-
accredited programs as well as between small and large
centers, making the analysis more complex. The only sta-
tistically significant interaction found, however, was
between the accreditation process and the year of trans-
plant for allogeneic HSCT. All other tested interactions,
including center size, EBMT risk score, age and GNI/cap,
were not statistically significant. Hence, our observations,
based on clustered survival models of individual patients
with identical characteristics, through stratification by
disease and conditioning regimen, clustering by center,
and modeling calendar year, risk score, age, donor rela-
tion and GNI/cap as covariates did respect the full diver-
sity of the patient populations and the teams. The analy-
sis showed that accreditation was associated with
improved outcome for all patients undergoing allogeneic
HSCT, pediatric or adult patients, in all diseases, in small
and large centers and in countries with low or high
GNI/cap. 
Not all factors known to influence outcome after HSCT
were included in the analysis, such as co-morbidity score,
viral status or cytokine polymorphisms; no adjustment
for modern HLA-typing of unrelated donors was made.
Similarly, the accreditation process did not assess all
potential factors influencing team performance.30 There
was, however, no hint of any additional interaction that
could explain the “JACIE” accreditation status as a simple
surrogate marker for an unknown unrelated effect. It is
therefore likely, with all the limitations of an observation-
al study, that the findings are indeed sufficiently unbiased
and robust; these results cannot be reduced to a simple
center effect, learning curve, cumulative experience or
case load.31-35 It remains possible that accredited centers
were more prone to quality work and that accreditation
remains a surrogate marker of quality consciousness.
Nevertheless, the data showed a close relationship
between the individual steps of the accreditation process
and the improvements; they showed a clear difference in
speed of improvement over calendar time between
accredited and non-accredited centers. These observa-
tions over a long time-span are evidence for a more causal
than casual relationship. 
The absence of a “JACIE effect” after autologous HSCT
requires an explanation. The analysis was focused on sur-
vival, the strongest and most unambiguous endpoint;
potential effects on quality of life, hospitalization time or
costs were not evaluated. Follow-up was significantly
shorter after autologous HSCT and in non-accredited cen-
ters (data not shown); more missing data might have
obscured potential effects. Cell processing, a crucial step
in autologous HSCT, was performed under a quality
management system for autologous HSCT as systemati-
cally imposed by most competent authorities, independ-
ently of “JACIE” accreditation; this might have reduced
potential effects. Transplant-related morbidity and mor-
tality rates are significantly lower for autologous than for
allogeneic HSCT, so that any change induced by the
implementation of a quality management system may be
more difficult to detect. Moreover, the time span of clini-
cal care under direct supervision of the transplant team
might have been too short to show a difference. Patient
and risk assessment by the transplant team begins long
before the transplant for patients with allogeneic HSCT
“JACIE” accreditation and outcome
haematologica | 2014; 99(5) 913
and care by the allogeneic transplant team continues, in
principle, lifelong.36 A quality management system
includes multiple elements. It includes description of
responsibilities, continuous quality improvement strate-
gies and error management; it mandates standard operat-
ing procedures for selection of patients (and donors),
transplant techniques, the stem cell product and follow-
up; it stipulates that data collection and data analysis are
integral parts of the therapy. Any quality management
system is, therefore, more likely to manifest its benefit
after the clinically more complex procedure of an allo-
geneic HSCT with its longer lasting link of patients to the
transplant team. 
Our observations support integration of a quality man-
agement system into complex medical therapeutic strate-
gies, including solid organ transplantation.37,38 The focus of
regulatory aspects should no longer be on center size alone
(minimal numbers of procedures being themselves require-
ments for “JACIE” accreditation) or on the sole use of cen-
ter-specific outcome data. Last, the clear differences
between autologous and allogeneic HSCT suggest the next
steps to take. Quality management should probably no
longer be restricted to just one phase of the treatment, the
immediate transplant period, but cover the whole treat-
ment program, from diagnosis to terminal care. The data
also show the complexity of any analysis. A simple com-
parison of outcome of patients treated with accredited ver-
sus non-accredited programs no longer suffices; however,
designing traditional randomized studies (“HSCT with ver-
suswithout a quality management system”) appears unfea-
sible in this context. The professional organizations are
challenged to provide the necessary framework and to
stimulate outcome research as an academic necessity.39
In summary, these data document that the use of a clin-
ical quality management system is associated with
improved survival of patients undergoing one form of
complex medical therapy: allogeneic HSCT. They support
the concept of a quality management system as a driver
for quality, hence better survival and suggest its broader
application in other fields of clinical medicine.
Acknowledgments
The authors acknowledge the cooperation of the participating
teams and their staff; the JACIE Accreditation Office in Barcelona,
the JACIE Board and Executive Committee, the JACIE Medical
Directors, the JACIE Accreditation Committee, all JACIE inspectors
and EBMT registered transplant programs that worked hard to
prepare and achieve JACIE accreditation; the EBMT presidents
and the working party chairs; the EBMT statistical office in Leiden;
the EBMT co-ordination offices in Barcelona, Paris and London ,
the Austrian Registry (ASCTR), the Czech BMT Registry, the
French Registry (SFGM-TC), the German Registry (DRST), the
Italian Registry (GITMO), the Dutch Registry (HOVON), the
Spanish BMT Registry (GETH), the Swiss Registry (SBST), the
Turkish BMT Registry and the British Registry (BSBMT).
Funding
This study was funded by the European Group for Blood and
Marrow Transplantation (EBMT) and the European Leukemia
Net (ELN). EBMT is supported by grants from the corporate
members: Amgen Europe, ViroPharma Europe, Celegene
International SARL, Genzyme Europe B.V., Gilead Sciences
Europe Ltd., Miltenyl Biotec GmbH, Schering-Plough
International Inc., Bristol Myers Squibb, CaridiaBCT Europe
NV, Cephalon Europe, F. Hoffmann-La Roche Ltd, Fresenius
Biotech GmbH, Therakos Inc.,  Alexion Europe,  Chugai Sanofi
– Aventis, Merck Sharp and Dohme, Novartis,  Pfizer, Pierre
Fabre Médicament. AG was in part supported by a grant from
the Bangerter Foundation on outcome research.
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
A. Gratwohl et al.
914 haematologica | 2014; 99(5)
References 
1. Buzzell RD, Gale BD, The PIMS Principles.
Linking Strategy to Performance. New York:
The Free Press; 1987.
2. Ryan J. Making the economic case for quali-
ty. An ASQ white paper. American Society
for Quality. (cited 2013 March 14). Available
from: http://rube.asq.org/pdf/economic-
case/economic-case.pdf.
3. Hendricks KB, Singhal VR. Does implement-
ing an effective TQM program actually
improve operating performance? Empirical
evidence from firms that have won quality
awards. Manage Sci. 1997;43 (9):1258-74.
4. Cole RE. What really happened to Toyota?
MIT Sloan Manage Rev. 2011;52(2):28-35.
5. Punnakitikashem P, Laosirihongthong T,
Adebanjo D, McLean MW. A study of qual-
ity management practices in TQM and non-
TQM firms: findings from the ASEAN auto-
motive industry. Int J Qual Reliab Manag.
2010;27(9):1021-35.
6. Phan AC, Abdallah AB, Matsui Y. Quality
management practices and competitive per-
formance: Empirical evidence from Japanese
manufacturing companies. Int J Prod Econ.
2011;133(2):518-29.
7. Talib F, Rahman Z. Impact of total quality
management and service quality in the
banking sector. J Telecomm Syst Manag.
2012;(2)1:1-5.
8. Khodosevych LT.  [Experience in the devel-
opment and implementation of a complex
quality management system for pharmaceu-
tical production and drug supply]. Farm Zh.
1978;6:21-5. 
9. Donabedian A. The effectiveness of quality
assurance. Int J Qual Health Care.
1996;8(4):401-7. Erratum in: Int J Qual
Health Care 1997;9(4):312
10. Westgard JO, Barry PL, Tomar RH.
Implementing total quality management
(TQM) in health-care laboratories. Clin Lab
Manage Rev. 1991;5(5):353-5,358-9,362-6
passim.
11. Stefl ME. The Toyota way to healthcare
excellence: increase efficiency and improve
quality with lean. Inquiry. 2009;46(1):109-10.
12. Rutledge J, Xu M, Simpson J. Application of
the Toyota production system improves
core laboratory operations. Am J Clin
Pathol. 2010;133(1):24-31.
13. Lopez F, Di Bartolo C, Piazza T Passannanti
A, Gerlach JC, Gridelli B, et al. A quality risk
management model approach for cell thera-
py manufacturing. Risk Anal. 2010;30(12):
1857-71.
14. Zahnd D, Leibundgut K, Zenhäusern R,
Pabst T, Fontana S, Schneider R, et al.
Implementation of the JACIE standards for a
haematopoietic progenitor cell transplanta-
tion programme: a cost analysis. Bone
Marrow Transplant. 2004;34(10):847-53.
15. Greenfield D, Pawsey M, Hinchcliff R,
Moldovan M, Braithwaite J. The standard of
healthcare accreditation standards: a review
of empirical research underpinning their
development and impact. BMC Health Serv
Res. 2012;12:329
16. Voelker R. Cancer care accreditation stan-
dards: improve quality and help patients
cope. JAMA. 2011;306(12):1314. 
17. Apperley J. Just another cost increasing exer-
cise (JACIE)? Bone Marrow Transplant.
2004;34(10):835-8.
18. Hinchcliff R, Greenfield D, Moldovan M,
Westbrook JI, Pawsey M, Mumford V, et al.
Narrative synthesis of health service accred-
itation literature. BMJ Qual Saf. 2012;21(12):
979-91.
19. McMahon LF Jr, Chopra V. Health care cost
and value: the way forward. JAMA. 2012;
307(7):671-2.
20. Shaw CD, Braithwaite J, Moldovan M,
Nicklin W, Grgic I, Fortune T, et al. Profiling
health-care accreditation organizations: an
international survey. Int J Qual Health Care.
2013;25(3):222-31.
21. Copelan EA. Hematopoietic stem-cell trans-
plantation. N Engl J Med. 2006;354(17):
1813-26. 
22. Appelbaum FR. Hematopoietic-cell trans-
plantation at 50. N Engl J Med. 2007;357
(15):1472-5. 
23. Gooley TA, Chien JW, Pergam SA,
Hingorani S, Sorror ML, Boeckh M, et al.
Reduced mortality after allogeneic
hematopoietic-cell transplantation. N Engl J
Med. 2010;363(22):2091-1.
24. Gratwohl A, Baldomero H, Aljurf M,
Pasquini MC, Bouzas LF, Yoshimi A, et al.
Hematopoietic stem cell transplantation: a
global perspective. JAMA. 2010;303(16):
1617-24.
25. Warkentin PI; Foundation for the
Accreditation of Cellular Therapy. Voluntary
accreditation of cellular therapies: Foundation
for the Accreditation of Cellular Therapy
(FACT). Cytotherapy. 2003;5(4): 299-305. 
26. Kvalheim G, Gratwohl A, Urbano-Ispizua
A; JACIE national representatives. JACIE
accreditation in Europe moves ahead.
Cytotherapy. 2003;5(4):306-8.  
27. Gratwohl A, Brand R, Niederwieser D,
Baldomero H, Chabannon C, Cornelissen J,
et al. Introduction of a quality management
system and outcome after hematopoietic
stem-cell transplantation. J Clin Oncol.
2011;29(15):1980-6. 
28. Gratwohl A. The EBMT risk score. Bone
Marrow Transplant. 2012;47(6):749-56.  
29. Gratwohl A, Hermans J, Goldman JM, Arcese
W, Carreras E, Devergie A, et al. Risk assess-
ment for patients with chronic myeloid
leukaemia before allogeneic blood or marrow
transplantation. Chronic Leukemia Working
Party of the European Group for Blood and
Marrow Transplantation. Lancet. 1998;352
(9134):1087-92.
30. Caunday O, Agulles O, McGrath E,
Empereur F, Stoltz JF, Chabannon C.
Implementation of JACIE accreditation
results in the establishment of new indica-
tors that unevenly monitor processes con-
tributing to the delivery of hematopoietic
SCT. Bone Marrow Transplant. 2013;38(4):
604-9.
31. Birkmeyer JD, Stukel TA, Siewers AE,
Goodney PP, Wennberg DE, Lucas FL.
Surgeon volume and operative mortality in
the United States. N Engl J Med. 2003;
349(22):2117-27.
32. Thiemann DR, Coresh J, Oetgen WJ, Powe
NR. The association between hospital vol-
ume and survival after acute myocardial
infarction in elderly patients. N Engl J Med.
1999;340(21):1640-8.
33. Biau DJ, Halm JA, Ahmadieh H, Capello
WN, Jeekel J, Boutron I, et al. Provider and
center effect in multicenter randomized con-
trolled trials of surgical specialties: an analy-
sis on patient-level data. Ann Surg. 2008;
247(5):892-8. 
34. Vinocur JM, Menk JS, Connett J, Moller JH,
Kochilas LK. Surgical volume and center
effects on early mortality after pediatric car-
diac surgery: 25-year north american experi-
ence from a multi-institutional registry.
Pediatr Cardiol. 2013;34(5):1226-36. 
35. Frassoni F, Labopin M, Powles R, Mary JY,
Arcese W, Bacigalupo A, et al. Effect of cen-
tre on outcome of bone-marrow transplan-
tation for acute myeloid leukaemia. Acute
Leukaemia Working Party of the European
Group for Blood and Marrow
Transplantation. Lancet. 2000;355(9213):
1393-8.
36. Majhail NS, Rizzo JD, Lee SJ, Aljurf M,
Atsuta Y, Bonfim C, et al. Recommended
screening and preventive practices for long-
term survivors after hematopoietic cell
transplantation. Biol Blood Marrow
Transplant. 2012;18(3):348-71.
37. Gratwohl A. Organ donation: stricter man-
agement of organ transplants. Nature.
2012;488(7412):459.
38. World Health Organization. WHO guiding
principles on human cell, tissue and organ
transplantation. Transplantation. 2010;90(3):
229-33. 
39. Barbui T, Björkholm M, Gratwohl A.
Optimizing investigator-led oncology
research in Europe. Haematologica. 2012;97
(6):800-4.
“JACIE” accreditation and outcome
haematologica | 2014; 99(5) 915
